The inflammatory response is among the most critical drivers of tissue damage and systemic dysfunction. Although corticosteroids (CS) can achieve symptom remission and prevent tissue damage, systemic side effects are an issue due to the lack of targeted drug delivery. To this end, we propose a new approach to delivering CS via a hyaluronic acid (HA)-cholesterol nanohydrogel (NHs). Cholesterol, responsible for the formation of NHs, facilitates interactions with CS, while HA interacts with CD44, which is overexpressed on inflammatory cells. The aforementioned NHs were shown to efficiently load dexamethasone (DEX), with 75% drug entrapment efficiency without inducing cytotoxicity in the murine macrophage RAW 264.7 cell line. The ability of DEX to reduce inflammatory cytokine levels in lipopolysaccharide-activated RAW 264.7 cells remained intact when it was loaded into NHs. The empty NHs themselves exhibited anti-inflammatory activity, likely due to the high molecular weight of the HA used in the formulation. Finally, further investigation into the role of HA in immune cell uptake revealed significantly higher internalization by activated macrophages, driven by HACD44 interactions, potentially enabling improved cellular targeting. This nanohydrogel system offers a promising, easily manufactured, and highly biocompatible solution for anti-inflammatory drug delivery.

CD44-targeted hyaluronic acid nanohydrogels enhance macrophage uptake and preserve the anti-inflammatory efficacy of dexamethasone / Migliorini, C., Cao, M., Domenichini, S., Hery, M., Tria, G., Silvestri, I., Matricardi, P., Di Meo, C., Fattal, E.. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 1873-3476. - 705:(2026), pp. 1-9. [10.1016/j.ijpharm.2026.127535]

CD44-targeted hyaluronic acid nanohydrogels enhance macrophage uptake and preserve the anti-inflammatory efficacy of dexamethasone

Claudia Migliorini;Pietro Matricardi
;
Chiara Di Meo;
2026

Abstract

The inflammatory response is among the most critical drivers of tissue damage and systemic dysfunction. Although corticosteroids (CS) can achieve symptom remission and prevent tissue damage, systemic side effects are an issue due to the lack of targeted drug delivery. To this end, we propose a new approach to delivering CS via a hyaluronic acid (HA)-cholesterol nanohydrogel (NHs). Cholesterol, responsible for the formation of NHs, facilitates interactions with CS, while HA interacts with CD44, which is overexpressed on inflammatory cells. The aforementioned NHs were shown to efficiently load dexamethasone (DEX), with 75% drug entrapment efficiency without inducing cytotoxicity in the murine macrophage RAW 264.7 cell line. The ability of DEX to reduce inflammatory cytokine levels in lipopolysaccharide-activated RAW 264.7 cells remained intact when it was loaded into NHs. The empty NHs themselves exhibited anti-inflammatory activity, likely due to the high molecular weight of the HA used in the formulation. Finally, further investigation into the role of HA in immune cell uptake revealed significantly higher internalization by activated macrophages, driven by HACD44 interactions, potentially enabling improved cellular targeting. This nanohydrogel system offers a promising, easily manufactured, and highly biocompatible solution for anti-inflammatory drug delivery.
2026
hyaluronic acid; CD44; amphiphilic polymers; nanohydrogels; dexamethasone; inflammation
01 Pubblicazione su rivista::01a Articolo in rivista
CD44-targeted hyaluronic acid nanohydrogels enhance macrophage uptake and preserve the anti-inflammatory efficacy of dexamethasone / Migliorini, C., Cao, M., Domenichini, S., Hery, M., Tria, G., Silvestri, I., Matricardi, P., Di Meo, C., Fattal, E.. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 1873-3476. - 705:(2026), pp. 1-9. [10.1016/j.ijpharm.2026.127535]
File allegati a questo prodotto
File Dimensione Formato  
Migliorini_CD44-targeted_2026.pdf

solo gestori archivio

Note: full text
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 3.94 MB
Formato Adobe PDF
3.94 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1779338
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact